Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET

References

• De Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld D K. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8: 57–60
   PubMed Web of Science ®Google Scholar
• Golling A, Egerer G, Lehnert T. Chirurgische Maßnahmen in diagnostik und therapie des M. Hodgkin. Onkologie 2000; 6: 1151–1159
   Google Scholar
• Hong S, Hahn J, Lee J, Bae S, Youn M. 18F-fluorodeoxyglucose positron emission tomography in the staging of malignant lymphoma compared with CT and 67-Ga scan. Yonsei Med J 2003; 44: 779–786
   PubMed Web of Science ®Google Scholar
• Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for the detection of lymphoma. J Nucl Med 1987; 28: 288–292
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Goldsmith S. Positron emission tomography in lymphoma: comparison with computed tomography and gallium-67 single photon emission computed tomography. Clin Lymphoma 2000; 1: 67–74
   PubMedGoogle Scholar
• Kostakoglu L, Goldsmith S. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung and colorectal carcinoma. J Nucl Med 2003; 44: 224–239
   PubMed Web of Science ®Google Scholar
• Haberkorn U, Strauss L G, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991; 32: 1485–1490
   PubMed Web of Science ®Google Scholar
• Haberkorn U, Strauss L G, Dimitrakopoulou A, et al. Fluorodeoxyglucose (FDG) imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993; 34: 12–17
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte M, Najjar F, Paulus P, Rigo P, Fillet G. Whole body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429–433
   PubMed Web of Science ®Google Scholar
• Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972–1980
   PubMed Web of Science ®Google Scholar
• O'Doherty M, Macdonald E, Barrington S, Mikhaeel N, Schey S. Positron emission tomography in the management of lymphomas. Clin Oncol 2002; 14: 415–426
   Web of Science ®Google Scholar
• Mier W, Haberkorn U, Eisenhut M. [18F]FLT: portrait of a proliferation marker. Eur J Nucl Med 2002; 29: 165–169
   Google Scholar
• Shields A, Grierson J, Dohmen B, et al. Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nat Med 1998; 4: 1334–1336
   PubMed Web of Science ®Google Scholar
• Dittmann H, Dohmen B M, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, Bares R. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002; 29: 1462–1469
   PubMed Web of Science ®Google Scholar
• Wagner M, Seitz U, Buck A, et al. 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in amurine B-cell lymphoma model and in the human disease. Cancer Res 2003; 63: 2681–2687
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Segall G. FDG PET imaging in patients with lymphoma: a clinical perspective. J Nucl Med 2001; 42: 609–610
   PubMed Web of Science ®Google Scholar
• Hoskin P. FDG PET in the management of lymphoma: a clinical perspective. Eur J Nucl Med 2002; 29: 449–451
   Google Scholar
• Lowe V, Wiseman G. Assessment of lymphoma treatment using 18F-FDG PET. J Nucl Med 2002; 43: 1028–1030
   PubMed Web of Science ®Google Scholar
• Canellos G. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6: 931–933
   PubMed Web of Science ®Google Scholar
• Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003; 44: 1225–1231
   PubMed Web of Science ®Google Scholar
• De Wit M, Bohuslavizki K, Buchert R, Bumann D, Clausen M, Hossfeld D. 18FDG-PET following treatment as valid predictor for disease free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29–37
   PubMed Web of Science ®Google Scholar
• Weihrauch M, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930–2934
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's Lymphoma. Ann Oncol 2002; 13: 1356–1363
   PubMed Web of Science ®Google Scholar
• Mikhaeel N, Timothy A, O'Doherty M, Hain S, Maisey M. 18FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 2000; 39: 543–553
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte M, Belhocine T, Hustinx R, Rigo P, Fillet G. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14: 123–130
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Coleman M, Leonard J, Kuji I, Zoe H, Goldsmith S. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43: 1018–1027
   PubMed Web of Science ®Google Scholar
• Buck A K, Halter G, Schirrmeister H, et al. Imaging prolfieration in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003; 44: 1426–1431
   PubMed Web of Science ®Google Scholar
• Been L B, Suurmeijer A J, Cobben D C, Jager P L, Hoekstra H J, Elsinga P H. [18F]FLT PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004; 31: 1659–1672
   PubMed Web of Science ®Google Scholar
• Tominaga K, Yamaguchi Y, Nozawa A, Abe M, Wakasa H. Proliferation in non-Hodgkin's lymphomas as determined by immunohistochemical double staining for Ki-67. Hematol Oncol 1992; 10: 163–169
   PubMed Web of Science ®Google Scholar
• Dittmann H, Dohmen B M, Paulsen F, et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003; 30: 1407–1412
   PubMed Web of Science ®Google Scholar
• Smyczek-Gargya B, Fersis N, Dittmann H, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004; 31: 720–724
   PubMed Web of Science ®Google Scholar
• Leskinen-Kallio S, Ruotsalainen U, Nagren K, Teras M, Joensuu H. Uptake of 18F-fluoro-tyrosine: preliminary evaluation and comparison with 18F-FDG. J Nucl Med 2003; 44: 533–539
   PubMed Web of Science ®Google Scholar
• Hustinx R, Lemaire C, Jerusalem G, et al. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG. J Nucl Med 2003; 44: 533–539
   PubMed Web of Science ®Google Scholar